Mansfield C, Gebben D, Sutphin J, Tepper SJ, Schwedt TJ, Sapra S, Shah N. Patient preferences for preventive migraine treatments: a discrete-choice experiment. Headache. 2019 Mar;59(5):715-26. doi: 10.1111/head.13498
Pajouheshnia R, van Smeden M, Peelen LM, Groenwold RHH. Variation in the measurement of predictors affects the discriminative ability and transportability of a prediction model. Presented at the Methods for Evaluation of Medical Prediction Models, Tests and Biomarkers (MEMTAB) 2018 Symposium; July 2, 2018. Utrecht, The Netherlands. [abstract] Diagn Progn Res. 2018 Jul 2; 2(Suppl 1):40. doi: 10.1186/s41512-018-0036-3
Damen JAAG, Debray TPA, Pajouheshnia R, Reitsma JB, Scholten RJPM, Moons KGM, Hooft L. Empirical evidence on the impact of study characteristics on the performance of prognostic models: a meta-epidemiological study. Presented at the Methods for Evaluation of Medical Prediction Models, Tests and Biomarkers (MEMTAB) 2018 Symposium; July 2, 2018. Utrecht, The Netherlands. [abstract] Diagn Progn Res. 2018 Jul 2; 2(Suppl 1):29-30. doi: 10.1186/s41512-018-0036-3
Pajouheshnia R, Schuster NA, Moons KGM, Rutten FH, Groenwold RHH, Peelen LM. Accounting for time-varying treatments when developing a prognostic model: a case study in patients treated with betablockers. Poster presented at the Methods for Evaluation of Medical Prediction Models, Tests and Biomarkers (MEMTAB) 2018 Symposium; July 2018. Utrecht, Netherlands. [abstract] Diagn Progn Res. 2018 Jul; 2(Supp1):28-9. doi: 10.1186/s41512-018-0036-3
Pajouheshnia R, Damen JAAG, Groenwold RHH, Moons KGM, Peelen LM. Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies. Diagn Progn Res. 2017 Sep 26;1:15. doi: 10.1186/s41512-017-0015-0
Hoffman V, Xue F, Green E, Eisele O, Kurth T, Seeger JD. Risk of cardiovascular events in migraine patients treated with prophylactic medications. Poster presented at the 59th Annual Scientific Meeting American Headache Society; June 8, 2017. Boston, MA. [abstract] Headache. 2017 Jun 7; 57(S3). doi: 10.1111/head.13102
Hoffman V, Xue F, Green E, Eisele O, Kurth T, Seeger JD. Risk of cerebrovascular events in migraine patients treated with prophylactic medications. Poster presented at the 59th Annual Scientific Meeting American Headache Society; June 8, 2017. Boston, MA. [abstract] Headache. 2017 Jun 7; 57(S3). doi: 10.1111/head.13102
Clark M, Schwedt TJ, Tepper SJ, Harris N, Martin S, Sapra S, Shah N. Patient satisfaction with prophylactic migraine medications. Poster presented at the 59th Annual Scientific Meeting American Headache Society; June 2017. Boston, MA. [abstract] Headache. 2017 Jun; 57(Suppl S3):133.
Heus P, Damen JAAG, Pajhouheshnia R, Scholten RJPM, Reitsma JM, Collins GS, Altman DG, Moons KGM, Hooft L. More than half of the TRIPOD items are inadequately reported in prediction modelling studies. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 19, 2016. Birmingham, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):27. doi: 10.1186/s41512-016-0001-y
Pajouheshnia R, Groenwold R, Moons K, Reitsma J, Peelen L. The effects of treatment use when externally validating a prediction model that did not include treatment as predictor. Presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; February 2016. Birmingham, United Kingdom. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):12. doi: 10.1186/s41512-016-0001-y
Pajouheshnia R, Damen J, Groenwold R, Moons K, Peelen L. How treatment use is addressed in prognostic research: a systematic review. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 19, 2016. Birmingham, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):19. doi: 10.1186/s41512-016-0001-y
Damen JAAG, Debray TPA, Heus P, Hooft L, Moons KGM, Pajouheshnia R, Reitsma JB, Scholten RJPM. Design characteristics of external validation studies influencing the performance of risk prediction models. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 2016. Birmingham, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):21. doi: 10.1186/s41512-016-0001-y
Damen JAAG, Debray TPA, Heus P, Hooft L, Moons KGM, Pajouheshnia R, Reitsma JB, Scholten RJPM. Performance of the Framingham risk models and pooled cohort equations for the prediction of cardiovascular disease in the general population: a meta-analysis. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 19, 2016. Birmington, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):20-1. doi: 10.1186/s41512-016-0001-y
Gonzalez JM, Johnson FR, Runken MC, Poulos CM. Evaluating migraineurs' preferences for migraine treatment outcomes using a choice experiment. Headache. 2013 Nov;53(10):1635-50.
Coon CD, Fehnel SE, Davis KH, Runken MC, Beach ME, Cady RK. The development of a survey to measure completeness of response to migraine therapy. Headache. 2012 Apr 1;52(4):550-72.
Fehnel SE, Coon CD, Davis KH, Runken MC, Cady RK. Development and Psychometric Evaluation of the Migraine Completeness of Response Survey (CORS). Poster presented at the 52nd Annual Scientific Meeting of the American Headache Society; June 2010. [abstract] Headache. 2010 Aug; 50(s1):S49-50.
Hartmaier SL, Demuro-Mercon C, Linder S, Winner P, Santanello NC. Development of a brief 24-hour adolescent migraine functioning questionnaire. Headache. 2001 Feb 1;41(2):150-6.